MX2022016532A - Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. - Google Patents

Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.

Info

Publication number
MX2022016532A
MX2022016532A MX2022016532A MX2022016532A MX2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A
Authority
MX
Mexico
Prior art keywords
polypeptides
modified
agonize
polypeptide
bind
Prior art date
Application number
MX2022016532A
Other languages
English (en)
Spanish (es)
Inventor
Katelyn M Willis
Bryan Becklund
Brendan P Eckelman
John C Timmer
Florian Sulzmaier
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2022016532A publication Critical patent/MX2022016532A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MX2022016532A 2020-07-02 2021-07-01 Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. MX2022016532A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047681P 2020-07-02 2020-07-02
PCT/US2021/040061 WO2022006380A2 (en) 2020-07-02 2021-07-01 Polypeptides comprising modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016532A true MX2022016532A (es) 2023-04-12

Family

ID=77127075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016532A MX2022016532A (es) 2020-07-02 2021-07-01 Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.

Country Status (12)

Country Link
US (1) US20230235005A1 (https=)
EP (1) EP4175979A2 (https=)
JP (1) JP2023532904A (https=)
KR (1) KR20230035076A (https=)
CN (1) CN116615440A (https=)
AR (1) AR122863A1 (https=)
AU (1) AU2021299552A1 (https=)
CA (1) CA3184618A1 (https=)
IL (1) IL299542A (https=)
MX (1) MX2022016532A (https=)
TW (1) TW202216745A (https=)
WO (1) WO2022006380A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
WO2023133393A1 (en) * 2022-01-05 2023-07-13 Inhibrx, Inc. Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
WO2023151661A1 (zh) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 免疫缀合物及其用途
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
US20240076343A1 (en) 2022-06-16 2024-03-07 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
KR20250143339A (ko) * 2023-02-06 2025-10-01 메르크 파텐트 게엠베하 VHH-기반 NKp46 결합제
AU2024330564A1 (en) 2023-08-30 2026-04-02 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性t細胞の増殖のためのインターロイキン-2変異タンパク質
ES2973548T3 (es) * 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
KR20250156190A (ko) * 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
US11492384B2 (en) * 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
SG11202106700WA (en) * 2019-01-07 2021-07-29 Inhibrx Inc Polypeptides comprising modified il-2 polypeptides and uses thereof
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS

Also Published As

Publication number Publication date
WO2022006380A2 (en) 2022-01-06
EP4175979A2 (en) 2023-05-10
TW202216745A (zh) 2022-05-01
WO2022006380A3 (en) 2022-02-24
KR20230035076A (ko) 2023-03-10
CN116615440A (zh) 2023-08-18
CA3184618A1 (en) 2022-01-06
AU2021299552A1 (en) 2023-02-02
AR122863A1 (es) 2022-10-12
US20230235005A1 (en) 2023-07-27
JP2023532904A (ja) 2023-08-01
IL299542A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022016532A (es) Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
MX2021008147A (es) Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.
WO2020247843A3 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
WO2020142659A3 (en) Multi-specific protein molecules and uses thereof
MX2011012184A (es) Polipeptidos bifuncionales.
MX2025010458A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
PH12022552436A1 (en) Immunoconjugates
SA519402463B1 (ar) بولي ببتيدات رابطة لمستقبل ترانسفيرين معالجة بالهندسة الوراثية
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
IL190705A0 (en) A method for the production of a permanent human cell line
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
WO2024073385A3 (en) Synthetic polypeptides and uses thereof
MX2021005540A (es) Peptidos inmunogenicos con motivos de oxidorreductasa mejorados.
WO2021188374A3 (en) Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
WO2023280307A9 (en) Mutant il-15 compositions and methods thereof
MX2023007519A (es) Receptores de celulas t especificos de mage-b2.
WO2020028572A3 (en) ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
WO2023056193A3 (en) Il-18 variants and uses thereof
BR112012011598A2 (pt) polipeptídeos de haemophilus parasuis e métodos de uso
WO2022226054A3 (en) Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
WO2020037181A3 (en) Cell sorting systems and methods of use
WO2022117692A3 (en) Ph-dependent mutant interleukin-2 polypeptides
BR112022010757A2 (pt) Região de anticorpo fc com afinidade de ligação aumentada para fc-gama-riib.